Mustafa TEKİN, Nejat AKAR, Şükrü CİN, Ömer UZUNALİ

Homozigot beta talasemide süperoksit dismütaz düzeyleri ve yüksek doz desferrioksamin tedavisinin etkisi

Bu çalışmada 15 homozigot beta talasemili hastada serumda MnSOD ve Cıı/ZnSOD düzeylerinin 10 sağlıklı kontrole göre farklı olup olmadığı ve hastalara verilen yüksek doz damar içi desferrioksamin (150 mg/kg) tedavisiyle MnSOD, Cu/ZnSOD düzeylerinde değişiklik olup olmadığı araştırıldı. Hastalarda bu değerleri etkileyebilecek serum ferritin, plazma ve kırmızı küre çinkosu, serum bakır düzeyi, alanın aminotransferaz, aspartat aminotransferaz düzeyleri ve desferrioksamin tedavisi sırasında idrarla atılan çinko ve bakır değerleri de ölçüldü. Hastaların MnSOD ve Cu/ZnSOD düzeyleri kontrollerden yüksek bulundu (p

Superoxide dismutase level in patients with homozygous beta thalassemia and desferrioxamine treatment

In this study, the MnSOD and Cu/ZnSOD serum levels of 75 homozygous beta thalassemia patients have been compared with those of 10 healthy controls. The effect of high dose intravenous desferrioxamine (150 mg/kg) treatment on MnSOD, Cu/ZnSOD levels of thalassemia patients has been observed. Serum ferritin, plasma and erythrocyte Zn, serum Cu levels, alanin aminotransferase, aspartate aminotransferase levels and values of Zn and Cu excreted by the urine during desferrioxamine therapy that could affect the MnSOD and Cu/Zn SOD levels in thalassemia patients have been evaluated. MnSOD and Cu/ZnSOD levels of patients have been higher than the controls (p

PDF

___

1. Shinar E, Rachmilfevvitz E.A. Oxidative denatııration of red blood cells in thalassemia. Semin Hematol, 1990;27(1 ):70-82
2. Yu B.P. Cellular defences against damage from reactive oxygen species. Physiol Rev,1994;74(1):139-162
3. Fosburg M.T, Nathan D.G. Treatment of cooley's anemia. Blood, 1990;76(3):435-444
4. Cohen A.R, Mizanin J, Schwartz E. Rapid removal of exces-sive ıron with daily, high dose IV chelation therapy. J Pediatr,1989;115:151-5
5. Davies S.C, Marcus R.E, Hungerford J.L, Miller M.H, Arden G.B, Huehns E.R. Ocular toxicity of high dose intrave-nous desferrioxamine. Lancet,1983;July 23; 181-84
6. Cohen A, Martin M, Mizanin ), Konkle D.F, Schvvartz E. Vi-sion and hearing during desferrioxamine therapy. J Pe-diatri 990;117:326-30
7. Olivieri N.F, Buncic J.R, Chew E. et al. Visual and auditory neurotoxicity in patients receiving SC DF infusions. N Engl J Med,1986;314:869-73
8. Porstmann T, VVietschke R, Schmechta R et al. A rapid and sensitive enzyme immunoassay for Cu/Zn superoxide dismutase vvith polyclonal and monoclonal antibodies. Clin Chim Açta 1988;171:1-10
9. Kawaguchi T, Suzuki Y, Matsuda T et al. Serum mangane-se-superoxide dismutase:normal values and increased levels in patients vvith acute myocardial infarction and several malignant diseases determined by an enzyme-linked immunosorbent assay using a monoclonal anti-body. J Immunol Meth 1990;127:249-254.
10. Perkin-Elmer. Clinical methods for atomic absorption spect-roscopy, determination of copper in serum, determina-tion of zinc in serum. Perkin-Elmer, Norvvalk 1971.
11. Mazotta D, Guarneri M, Fagioli F. Determination of zinc in serum, hair and urine in homozygous thalassemic pati-ents by atomic absorption spectrohotometry. İn Mazot-ta D: II Parmaco Ed Pr, 1986,41-42, 397-403
12. Rachmilevvitz E.A., Shifter A, Kahane I. Vitamin E deficiency in beta thalassemia majör. Changes in hematological and biochemical parameters after a therapotical trial vvith alfa tocopherol. Am J Clin Nutr,32:1850,1979
13. Shull S, Heintz N.H, Periasamy M. et al. Differential regula-tion of antioxidant enzymes in response to oxidants. J Biol Chem, 1991;266:24398-24403
14. Arcasoy A, Çavdar A.O. Changes of trace minerals(Serum iron, zinc, copper and magnesium) in thalassemia. Açta Haemat, 1975;53:341-346
15. Virgilis S.D, Congia M, Turco M.P. et al. Depletion of trace elements and acute ocular toxicity induced by DF in pa-tients vvith thalassemia. Arch Dis Child, 1988;63:250-255
16. Uysal Z, Akar N, Dinçer N, Cin Ş, Arcasoy A. Urinary zinc excretion in beta thalassemia majör patients vvith and vvithout hepatitis. Trace Elements Med,1994; 11 (3):153-154
17. Uysal Z, Akar N, Kemahlı S, Dinçer N, Arcasoy A. Desferri-oxamine and urinary zinc excretion in beta thalassemia majör. Ped Hematol Oncol,1993;10:257-260